Cyclic compounds
There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W—Ar (I) wherein, A is a group represented by the formula (A1) or (A2): (wherein, ring Aa is a 5- or 6-membered ring which may be further substituted; ring Ab is a 5- or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R 1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, —O—, —S—, etc.; Y 1 , Y 2 and Q are independently optionally substituted carbon or nitrogen; is a single or double bond); W is a bond, optionally substituted methylene, optionally substituted imino, —O—, —S—, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.
1. A compound represented by the formula:
A-W—Ar (I)
wherein, A is a group represented by the formula:
wherein R 1a is
(1) an amino which is mono- or di-substituted with
(i) a C 1-8 alkyl which may be substituted with a hydroxyl substituted with a C 1-8 alkyl,
a C 3-7 cycloalkyl, a phenyl, a 4-methylphenyl, a hydroxyl substituted with a phenyl,
a 2-chlorophenyl, a heterocyclic group, a 4-chlorophenyl, a 4-(benzyloxy)phenyl,
a 3-methoxyphenyl, a 3-chlorophenyl, a 2′-cyanobiphenyl, a naphthyl, a 2,5-dimethoxyphenyl,
a 3-fluoro-5-(trifluoromethyl)phenyl, an acyl, or an esterified or amidated carboxyl,
(ii) a C 2-8 alkenyl,
(iii) a C 1-10 acyl, or
(iv) a C 3-7 cycloalkyl, or
(2) a cyclic amino;
R 2 is a hydrogen, a C 1-8 alkyl which may be substituted by a cyano or a phenyl;
R 2′ is
(1) a hydrogen,
(2) an acetyl, or
(3) a C 1-8 alkyl which may be substituted with a phenyl, a 4-methoxyphenyl or an acetyl;
W is a bond; and
Ar is a phenyl which is substituted with
(i) one or more C 1-8 alkyl which may be substituted with one or more halogen,
(ii) one or more alkoxy,
(iii) one or more halogen,
(iv) one or more benzyloxy, or
(v) one or more hydroxy;
or a salt thereof.
2. The compound according to claim 1 , wherein the compound is 2-(dipropylamino)-5-mesityl-3,7-dimethyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one.
3. A method for treating a disease wherein a CRF receptor is implicated, which comprises administering to a subject in need thereof an effective amount of a compound or salt according to claim 1 , wherein the disease being treated is selected from the group consisting of affective disorder, depression and anxiety.
4. A pharmaceutical composition comprising the compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.
5. The compound according to claim 1 , wherein R 1a is
(1) an amino which is mono- or di-substituted with
(i) a C 1-8 alkyl which may be substituted with a methoxy, a cyclopropyl, a phenyl,
a 4-methylphenyl, a phenoxy, a 2-chlorophenyl, a pyridyl, a 4-chlorophenyl,
a 4-(benzyloxy)phenyl, a 3-methoxyphenyl, a 3-chlorophenyl, a 2′-cyanobiphenyl, a pyrrolyl,
a naphthyl, a 2,5-dimethoxyphenyl, a quinolinyl, a 3-fluoro-5-(trifluoromethyl)phenyl,
a benzoyl, an ethoxycarbonyl, or an N,N-dimethylcarbamoyl,
(ii) a C 2-8 alkenyl,
(iii) a C 1-10 acyl, or
(iv) a C 3-7 cycloalkyl,
(2) a piperidinyl,
(3) a pyrrolidinyl, or
(4) a morpholinyl.
6. The compound according to claim 1 , wherein R 1a is an amino which is mono- or di-substituted with a C 1-8 alkyl.
7. The compound according to claim 1 , wherein R 2 is a C 1-8 alkyl.
8. The compound according to claim 1 , wherein R 2′ is a C 1-8 alkyl.
9. The compound according to claim 1 , wherein Ar is a phenyl which is substituted with one or more C 1-8 alkyl.
10. The compound according to claim 1 , wherein R 1a is an amino group which is mono- or di-substituted with a C 1-8 alkyl;
R 2 is a C 1-8 alkyl;
R 2′ is a C 1-8 alkyl; and
Ar is a phenyl which is substituted with one or more C 1-8 alkyl.